Stockscreener 앱 받기
1.805
4.50%
-0.085
시간 외 거래:
1.81
0.005
+0.28%
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics Inc. Stock Analysis and ForecastLightning-fast growth - jammulinksnews.com
BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
What drives BioXcel Therapeutics Inc. stock priceSky-high return potential - Autocar Professional
What analysts say about BioXcel Therapeutics Inc. stockHigh-octane investment gains - Autocar Professional
Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest
BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com Australia
BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan
First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan
Is BioXcel Therapeutics Inc. a good long term investmentRobust investment performance - printweek.in
How high can BioXcel Therapeutics Inc. stock price go in 2025Capital Growth Picks - beatles.ru
why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest
BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus
BioXcel Therapeutics (BTAI) Gains Patent Approval, Price Target Affirmed | BTAI Stock News - GuruFocus
BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent By Investing.com - Investing.com South Africa
BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent - Investing.com Nigeria
BioXcel Granted Patent for Dexmedetomidine Use - TipRanks
Why BioXcel Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser
BioXcel wins USPTO nod; 14th Igalmi patent secures exclusivity to 2043 | BTAI SEC FilingForm 8-K - Stock Titan
How BioXcel Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress - Insider Monkey
12 Best Fundamentally Strong Penny Stocks to Invest in - Insider Monkey
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
NIP Group, Hyatt, BioXcel Therapeutics - TradingView
BioXcel Therapeutics rises on positive schizophrenia drug trial recommendation - TradingView
Why BioXcel Therapeutics Is Rising In Pre-market? - Nasdaq
BioXcel’s BXCL501 agitation treatment trial continues after safety review By Investing.com - Investing.com Canada
BioXcel’s BXCL501 agitation treatment trial continues after safety review - Investing.com
Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia - TradingView
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - TradingView
Bioxcel Therapeutics Plunges 11.71% Post Reverse Split - AInvest
Lucid Capital Sees Promising Future for BioXcel Therapeutics (BT - GuruFocus
Is BioXcel Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
BioXcel stock price target raised to $8 from $3 at H.C. Wainwright - Investing.com India
BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent
BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN
BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus
Class Suit Against AI Drugmaker Back On After Mediation Fails - Law360
0.51%
자본화:
|
볼륨(24시간):